Gordie Nye News

Atlantic Therapeutics appoints Gordie Nye as Chairman

Seroba’s investee company, Atlantic Therapeutics, which is focused on treating conditions of the pelvic floor and surrounding tissues, has appointed Gordie Nye as its Chairman.

After working with Gillette and Reebok, Gordie Nye forged his career as a CEO and Director of venture and private equity-backed medical device start-ups and buyouts. Of particular note are A-Company Orthodontics, Critikon and ZELTIQ Aesthetics, all of which saw excellent returns for investors. Nye is currently CEO of R2 Dermatology, a start-up that is set to commercialise a Harvard University technology – familiar territory for Nye who did the same at ZELTIQ, the maker of CoolSculpting, arguably the most valuable device company in the Aesthetics industry.

Atlantic Therapeutics CEO, Steve Atkinson, previously teamed up with Nye at ZELTIQ and Critikon. Atkinson says: “I am delighted Gordie has joined Atlantic Therapeutics as Chairman.  His involvement is an endorsement of the huge potential for INNOVO® and Gordie’s expertise in marketing medical devices to consumers will be invaluable to management as we strive to build value for our company and investors.”

Nye says “Typically resulting in incontinence and/or poor sexual health, a weak pelvic floor adversely affects the dignity, social life, and relationships of millions of people. Few conditions are so widespread yet so poorly served by the healthcare industry.  Surgery is a last resort, and conservative treatments in this category typically involve internally inserted devices that can be embarrassing and are unpleasant to use.  INNOVO® is safe, effective, wearable, and is an embarrassment-free device to restore pelvic floor strength.  As Chairman of Atlantic Therapeutics, I look forward to working with Steve and his team to achieve widespread adoption of INNOVO®.”

Ends.

For further information: Please contact Vicky La Touche-Price, Seroba Life Sciences on +353 1 6334028 or visit RestoreTheFloor.

Recent Articles

Cancer Killers

Fusion Pharmaceuticals Announces Pricing of Initial Public Offering.

HAMILTON, ONTARIO and Boston. 25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation […]

Read More
Alflorex Zenflore V2

Novozymes acquires PrecisionBiotics Group.

25 June 2020.  Seroba’s portfolio company, PrecisionBiotics Group has been acquired by Novozymes. Based in Cork, Ireland, PrecisionBiotics Group holds […]

Read More
The Big Taboo

New U.K. Study Offers Good News to Sufferers During World Continence Week

A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective […]

Read More
Shorla Pharma

Shorla Pharma Closes $8.3m Series A Funding Round

Dublin and Clonmel, Ireland. June 4, 2020.   Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top